Syndesi Therapeutics
company
About
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- €3.20M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€3.20M
Syndesi Therapeutics has raised a total of
€3.20M
in funding over 2 rounds. Their latest funding was raised on
Mar 20, 2019 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 20, 2019 | Grant | €3.20M | 1 |
|
— | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
